Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

SLE · Systemic Sclerosis · IIM · NMOSD · MS · MG · ANCA Associated Vasculitis (AAV)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First People's Hospital of Lianyungang, Lianyungang, Jiangus, China
Contact: Study coordinator (Huijie Liu) · liuhj1971@126.com · +86 18961326135

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies

Abroad (travel likely)RecruitingPHASE1

Tianjin, China

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Systemic Lupus Erythematosus (SLE) · Immune-mediated Necrotizing Myopathy (IMNM) · Neuromyelitis Optica Spectrum Disorders (NMOSD)

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Rheumatic Diseases · Rheumatoid Arthritis (RA) · Giant Cell Arteritis (GCA)

Abroad (travel likely)Recruiting

Bonn, Germany

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome

Abroad (travel likely)RecruitingPHASE1

Hangzhou, China